As the pharmaceutical industry continues to externalize drug discovery, the need to verify data provided by CROs has become a rate limiting step in the discovery process. Data from trusted partners is accepted without review to allow confirmation of data from new CROs. The Bruker Arxspan and Mestrelab platform now allows automation of both structural confirmation and purity upon data submission. This provides improved fidelity of data and introduces new capabilities such as alerting scientists to deviations in the expected data
